Table 2 Patient disposition at the end of observation (SAS)
Disposition/reason | Pazopanib N = 190 n (%) |
|---|---|
Enrolled | 190 (100.0) |
Completed observational period | 78 (41.1) |
Discontinued in observational period | 112 (58.9) |
Primary reason for discontinuation in observational period | |
Adverse event | 10 (5.3) |
Progressive disease | 57 (30.0) |
Lost to follow-up | 8 (4.2) |
Death | 25 (13.2) |
Patient/guardian decision | 5 (2.6) |
Physician decision | 2 (1.1) |
Withdrawal of consent | 7 (3.7) |
Unknown | 5 (2.6) |